<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03693378</url>
  </required_header>
  <id_info>
    <org_study_id>PanFAM-1</org_study_id>
    <nct_id>NCT03693378</nct_id>
  </id_info>
  <brief_title>A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups</brief_title>
  <official_title>A Prospective, Multi-center Investigational Study of IMMray™ PanCan-d Diagnostic Assay for Early Detection of Pancreatic Ductal Adenocarcinoma in High-risk Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunovia, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunovia, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PanFAM-1 is a clinical study for early detection of pancreatic cancer in high-risk groups.&#xD;
      The goals of the study are to assess the performance and diagnostic accuracy of the IMMray™&#xD;
      PanCan-d test compared to standard-of-care imaging.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PanFAM-1 is a prospective, multi-center, investigational study, designed to assess the&#xD;
      performance of the IMMray™ PanCan-d test in early detection of pancreatic ductal&#xD;
      adenocarcinoma (PDAC) in high-risk populations. Specifically, the IMMray PanCan-d test uses&#xD;
      state of the art machine learning algorithms to condense the multiple fluorescence data&#xD;
      points generated by the test to a simple yes/no result. Thus, a highly complex statistical&#xD;
      model uses the multi-dimensional nature of the test to generate a score, which is called a&#xD;
      decision value. The score is compared to the established cut-off value for the test to inform&#xD;
      the operator whether the patient sample is positive or negative for PDAC. This study will&#xD;
      validate and evaluate the performance of the IMMray PanCan-d test in comparison to standard&#xD;
      of care imaging approaches that are currently used in PDAC disease surveillance. Subjects in&#xD;
      this study will be recruited from several European and North American research sites that&#xD;
      have a PDAC surveillance program or established protocol for monitoring individuals&#xD;
      considered to be at a high-risk for developing pancreatic cancer. Any subject that shows&#xD;
      disease progression while on-study will be removed from the study to receive standard of care&#xD;
      per institutional guidelines. Overall, this study poses minimal risk to subjects. The&#xD;
      PanFAM-1 study is an adaptive study design over two approximately 18 month intervals, which&#xD;
      are separated by an interim analysis to evaluate diagnostic accuracy of the IMMray PanCan-d&#xD;
      test. This study is an observational period in which blood collections from eligible subjects&#xD;
      will be evaluated using the IMMray PanCan-d test. Subjects will undergo scheduled imaging&#xD;
      assessment and clinical evaluation consistent with the resarch sites' PDAC surveillance&#xD;
      program. Subject data derived from the IMMray PanCan-d test during this portion of the study&#xD;
      will be delayed from time of initial blood collection until the samples are analyzed. The&#xD;
      analysis will compare IMMray PanCan-d test results for each subject to corresponding imaging&#xD;
      assessments performed as part of standard of care PDAC surveillance. The study will only&#xD;
      proceed to the interventional period if the interim analysis indicates that the diagnostic&#xD;
      accuracy of the IMMray PanCan-d test is capable of detecting PDAC in high-risk subjects with&#xD;
      the same or better ability as standard of care imaging. If at any time imaging assessments&#xD;
      are considered positive for clinical disease then, regardless of IMMray PanCan-d test&#xD;
      results, subjects will be managed according to institutional guidelines. All scheduled blood&#xD;
      collections for purposes of this study will be halted and subjects will be removed from the&#xD;
      study upon confirmation of PDAC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 19, 2016</start_date>
  <completion_date type="Anticipated">September 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Validation of IMMray™ PanCan-d test</measure>
    <time_frame>Approximately 18 months upon collection of approximately 2,000 subjects, or disease progression, whichever comes first</time_frame>
    <description>Demonstrate that the IMMray PanCan-d test is equal or better than the reference standard imaging procedures for early detection of PDAC in asymptomatic high risk individuals</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the IMMray™ PanCan-d test performance</measure>
    <time_frame>Approximately 18 months upon collection of approximately 2,000 subjects, or disease progression, whichever comes first</time_frame>
    <description>Point Estimates and 95% confidence intervals</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <condition>Familial Pancreatic Cancer</condition>
  <condition>FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        High-risk patient population, enrolled in established PDAC screening programs&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
          2. Individuals with the following family phenotype and age:&#xD;
&#xD;
               1. Two or more relatives with pancreatic adenocarcinomas (PDAC) on the same side of&#xD;
                  the family, where two PDAC-affected individuals are first degree related (FDR) +&#xD;
                  at least one PDAC-affected individual is a FDR of the Participant (≥50 years old&#xD;
                  OR 10 years before onset in family)&#xD;
&#xD;
               2. Two affected FDR with PDAC (≥50 years old OR 10 years before onset of an FDR)&#xD;
&#xD;
               3. Any of BRCA1, BRCA2, PALB2, ATM mutations confirmed pathogenic or likely&#xD;
                  pathogenic + one FDR or secondary degree related (SDR) with PDAC (≥50 years old&#xD;
                  OR 10 years before onset of an FDR and SDR)&#xD;
&#xD;
               4. Familial atypical multiple mole-melanoma (FAMMM) with confirmed pathogenic or&#xD;
                  likely pathogenic mutation variants in: p16, CDKN2A (≥50 years old)&#xD;
&#xD;
               5. Known mutation carrier for STK11 (Peutz Jeghers Syndrome) (≥35 years old)&#xD;
&#xD;
               6. Lynch syndrome (HNPCC) with confirmed pathogenic or likely pathogenic variants&#xD;
                  in: MLH1, MSH2, MSH6, PMS2, or EPCAM + one FDR or SDR with PDAC (≥50 years old OR&#xD;
                  10 years before onset of an FDR or SDR)&#xD;
&#xD;
               7. Hereditary pancreatitis with confirmed PRSS1 pathogenic or likely pathogenic&#xD;
                  history of pancreatitis (≥40 years old)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf Ehrnström</last_name>
    <role>Study Director</role>
    <affiliation>Immunovia, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Gastroenterology and Hepatology</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8327</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029-6574</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-6061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-2582</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Research Institute of the McGill University Health Centre</name>
      <address>
        <city>Montréal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Santiago De Compostela</name>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umeå University Hospital</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Collage London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mellby LD, Nyberg AP, Johansen JS, Wingren C, Nordestgaard BG, Bojesen SE, Mitchell BL, Sheppard BC, Sears RC, Borrebaeck CAK. Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer. J Clin Oncol. 2018 Oct 1;36(28):2887-2894. doi: 10.1200/JCO.2017.77.6658. Epub 2018 Aug 14.</citation>
    <PMID>30106639</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 1, 2018</study_first_submitted>
  <study_first_submitted_qc>October 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high-risk familial</keyword>
  <keyword>screening program</keyword>
  <keyword>pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Dysplastic Nevus Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

